What is CHRS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.17B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CHRS?

P/E (TTM) is n/a and 52-week range is $0.97 to $2.62 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CHRS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CHRS?

The company profile lists revenue (TTM) near $51M, net income (TTM) near $-13.16B, EPS (TTM) near $-1.03 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Coherus Oncology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Redwood City, California, US, 154.3M shares outstanding, ISIN US19249H1032 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 147 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

Employees

147

Website

www.coherus.com/

IPO

2014-11-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)